Portal de Periódicos da CAPES

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

2015; Springer Nature; Volume: 112; Issue: 10 Linguagem: Inglês

10.1038/bjc.2015.137

1532-1827

M R Sarduy, Imalvet Santiesteban García, Marco A. Coca, Abel Hernández Perera, Loida Torres, Carmen Valenzuela, Idania Baladrón, Margarita Solares, Virginia Reyes, Ignacio Hernández, Yasser Perera, Yency Martinez, Laura Molina, Yaima Matas, Julio Ancízar, A. Prats, Luis Javier González, C A Casacó, Boris Acevedo, Pedro López‐Saura, Daniel F. Alonso, Roberto Gómez, S E Perea-Rodríguez,

Immunotherapy and Immune Responses

We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2-antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic activity and identify the recommended dose. Fourteen patients were treated with intralesional injections containing 35 or 70 mg of CIGB-300 in three alternate cycles of three consecutive days each before standard chemoradiotherapy. Tumour uptake was determined using 99Tc-radiolabelled peptide. In situ B23/nucleophosmin was determined by immunohistochemistry. Maximum tumour uptake for CIGB-300 70-mg dose was significantly higher than the one observed for 35 mg: 16.1±8.9 vs 31.3±12.9 mg (P=0.01). Both, AUC24h and biological half-life were also significantly higher using 70 mg of CIGB-300 (P<0.001). Unincorporated CIGB-300 diffused rapidly to blood and was mainly distributed towards kidneys, and marginally in liver, lungs, heart and spleen. There was no DLT and moderate allergic-like reactions were the most common systemic side effect with strong correlation between unincorporated CIGB-300 and histamine levels in blood. CIGB-300, 70 mg, downregulated B23/nucleophosmin (P=0.03) in tumour specimens. Intralesional injections of 70 mg CIGB-300 in two sites (0.5 ml per injection) and this treatment plan are recommended to be evaluated in phase 2 studies.